Suppr超能文献

结直肠癌的免疫治疗。

Immunotherapy for colorectal cancer.

机构信息

Shigeo Koido, Toshifumi Ohkusa, Kazuki Takakura, Keisuke Saito, Zensho Ito, Hiroko Kobayashi, Mikio Kajihara, Kan Uchiyama, Seiji Arihiro, Hisao Tajiri, Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Chiba 277-8567, Japan.

出版信息

World J Gastroenterol. 2013 Dec 14;19(46):8531-42. doi: 10.3748/wjg.v19.i46.8531.

Abstract

The incidence of colorectal cancer (CRC) is on the rise, and the prognosis for patients with recurrent or metastatic disease is extremely poor. Although chemotherapy and radiation therapy can improve survival rates, it is imperative to integrate alternative strategies such as immunotherapy to improve outcomes for patients with advanced CRC. In this review, we will discuss the effect of immunotherapy for inducing cytotoxic T lymphocytes and the major immunotherapeutic approaches for CRC that are currently in clinical trials, including peptide vaccines, dendritic cell-based cancer vaccines, whole tumor cell vaccines, viral vector-based cancer vaccines, adoptive cell transfer therapy, antibody-based cancer immunotherapy, and cytokine therapy. The possibility of combination therapies will also be discussed along with the challenges presented by tumor escape mechanisms.

摘要

结直肠癌(CRC)的发病率呈上升趋势,而复发性或转移性疾病患者的预后极差。虽然化疗和放疗可以提高生存率,但必须整合免疫疗法等替代策略,以改善晚期 CRC 患者的预后。在这篇综述中,我们将讨论免疫疗法诱导细胞毒性 T 淋巴细胞的作用,以及目前正在临床试验中的 CRC 的主要免疫治疗方法,包括肽疫苗、基于树突状细胞的癌症疫苗、全肿瘤细胞疫苗、基于病毒载体的癌症疫苗、过继细胞转移疗法、抗体类癌症免疫疗法和细胞因子疗法。还将讨论联合治疗的可能性,以及肿瘤逃逸机制带来的挑战。

相似文献

1
Immunotherapy for colorectal cancer.
World J Gastroenterol. 2013 Dec 14;19(46):8531-42. doi: 10.3748/wjg.v19.i46.8531.
2
Immunotherapy for metastatic colorectal cancer: present status and new options.
Scand J Gastroenterol. 2012 Mar;47(3):315-24. doi: 10.3109/00365521.2012.640831. Epub 2012 Jan 3.
3
Immunotherapy in human colorectal cancer: Challenges and prospective.
World J Gastroenterol. 2016 Jul 28;22(28):6362-72. doi: 10.3748/wjg.v22.i28.6362.
4
Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
Cancer Lett. 2016 Oct 10;381(1):259-68. doi: 10.1016/j.canlet.2016.02.057. Epub 2016 Mar 8.
5
[Immunotherapy for colorectal cancer].
Bull Cancer. 2013 Sep;100(9):871-85. doi: 10.1684/bdc.2013.1800.
6
Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.
World J Gastroenterol. 2016 May 14;22(18):4446-58. doi: 10.3748/wjg.v22.i18.4446.
7
Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.
Dis Markers. 2022 Feb 15;2022:8270305. doi: 10.1155/2022/8270305. eCollection 2022.
8
Checkpoints and beyond - Immunotherapy in colorectal cancer.
Semin Cancer Biol. 2019 Apr;55:78-89. doi: 10.1016/j.semcancer.2018.04.003. Epub 2018 Apr 30.
9
The potential role of immunotherapy to treat colorectal cancer.
Expert Opin Investig Drugs. 2015 Mar;24(3):329-44. doi: 10.1517/13543784.2015.985376. Epub 2014 Dec 17.
10
Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy.
Front Immunol. 2020 May 28;11:1052. doi: 10.3389/fimmu.2020.01052. eCollection 2020.

引用本文的文献

1
Advances in cancer nanovaccines: a focus on colorectal cancer.
Nanomedicine (Lond). 2025 May;20(9):1029-1041. doi: 10.1080/17435889.2025.2486930. Epub 2025 Apr 5.
3
5
Identification of Gene Signature-Related Oxidative Stress for Predicting Prognosis of Colorectal Cancer.
Oxid Med Cell Longev. 2023 Feb 7;2023:5385742. doi: 10.1155/2023/5385742. eCollection 2023.
8
The Mycobiome: Cancer Pathogenesis, Diagnosis, and Therapy.
Cancers (Basel). 2022 Jun 10;14(12):2875. doi: 10.3390/cancers14122875.
10
Comparison of four methods of colon cancer cell lysates preparation for maturation of dendritic cells.
Res Pharm Sci. 2021 Nov 11;17(1):43-52. doi: 10.4103/1735-5362.329925. eCollection 2022 Feb.

本文引用的文献

1
2
Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.
World J Gastroenterol. 2013 Aug 21;19(31):5051-60. doi: 10.3748/wjg.v19.i31.5051.
3
Ex vivo generation of highly purified and activated natural killer cells from human peripheral blood.
Hum Gene Ther Methods. 2013 Aug;24(4):241-52. doi: 10.1089/hgtb.2012.183.
5
Nivolumab plus ipilimumab in advanced melanoma.
N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.
6
Antibody-based therapy in colorectal cancer.
Immunotherapy. 2013 May;5(5):533-45. doi: 10.2217/imt.13.35.
7
NK cell-based immunotherapy for malignant diseases.
Cell Mol Immunol. 2013 May;10(3):230-52. doi: 10.1038/cmi.2013.10. Epub 2013 Apr 22.
8
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies.
Front Immunol. 2013 Mar 27;4:76. doi: 10.3389/fimmu.2013.00076. eCollection 2013.
9
Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.
Int J Cancer. 2013 Oct 1;133(7):1643-52. doi: 10.1002/ijc.28163. Epub 2013 Apr 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验